Literature DB >> 8049828

Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation.

M W Konstan1, K A Hilliard, T M Norvell, M Berger.   

Abstract

To determine the extent of airway infection and inflammation in adolescents and adults with cystic fibrosis (CF) who have mild lung disease and are without symptoms of active infection, we performed bronchoalveolar lavage (BAL) on 18 CF patients > or = 12 yr of age who were stable, appeared clinically well, and had mean (+/- SEM) FEV1 of 79 +/- 4% of predicted. We quantitated the bacteria, inflammatory cells, immunoglobulins, and mediators of inflammatory tissue damage in the epithelial lining fluid (ELF) of these patients and in 23 healthy control subjects. All CF patients were found to be infected with Pseudomonas aeruginosa, Staphylococcus aureus, and/or Haemophilus influenzae; no organisms were isolated from the control subjects. The mean number of cells in the ELF was 14 times greater in the CF patients than in the control subjects. Neutrophils constituted 57% of the recovered cells in the CF patients versus 3% in the control subjects, and their concentration was 380 times greater in the CF patients versus the control subjects. IgG, IgA, and IgM were 2.5 to 6 times greater in CF ELF versus that of control subjects. Abundant active elastase was present in the ELF of the CF patients (2.3 +/- 0.9 microM) despite threefold elevated levels of alpha 1-protease inhibitor (alpha 1-PI). No active elastase was detectable in the control subjects. alpha 1-PI was functional in CF as demonstrated by elevated elastase:alpha 1-PI complex (0.045 microM in CF versus 0.002 microM in control subjects). This active elastase caused proteolytic destruction of surface complement receptors on airway neutrophils in situ.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8049828     DOI: 10.1164/ajrccm.150.2.8049828

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  145 in total

Review 1.  Physiotherapy in cystic fibrosis.

Authors:  S A Prasad; E L Tannenbaum; C Mikelsons
Journal:  J R Soc Med       Date:  2000       Impact factor: 5.344

2.  Quantitative analysis of inflammatory cells infiltrating the cystic fibrosis airway mucosa.

Authors:  C Hubeau; M Lorenzato; J P Couetil; D Hubert; D Dusser; E Puchelle; D Gaillard
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

Review 3.  The Microbiome and the Respiratory Tract.

Authors:  Robert P Dickson; John R Erb-Downward; Fernando J Martinez; Gary B Huffnagle
Journal:  Annu Rev Physiol       Date:  2015-11-02       Impact factor: 19.318

Review 4.  The Tools of the Trade - Uses of Flexible Bronchoscopy.

Authors:  Varinder Singh; Kamal Kumar Singhal
Journal:  Indian J Pediatr       Date:  2015-08-20       Impact factor: 1.967

5.  Increase in exhaled carbon monoxide during exacerbations of cystic fibrosis.

Authors:  J D Antuni; S A Kharitonov; D Hughes; M E Hodson; P J Barnes
Journal:  Thorax       Date:  2000-02       Impact factor: 9.139

6.  Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study.

Authors:  V Thompson; N Mayer-Hamblett; M Kloster; D Bilton; P A Flume
Journal:  J Cyst Fibros       Date:  2015-02-25       Impact factor: 5.482

7.  Bronchoalveolar fluid is not a major hindrance to virus-mediated gene therapy in cystic fibrosis.

Authors:  C P Rooney; G M Denning; B P Davis; D M Flaherty; J A Chiorini; J Zabner
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

Review 8.  Use of modulators of airways inflammation in patients with CF.

Authors:  Clement L Ren
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

Review 9.  The role of inflammation in the pathophysiology of CF lung disease.

Authors:  James F Chmiel; Melvin Berger; Michael W Konstan
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

10.  The GO system prevents ROS-induced mutagenesis and killing in Pseudomonas aeruginosa.

Authors:  Laurie H Sanders; Julee Sudhakaran; Mark D Sutton
Journal:  FEMS Microbiol Lett       Date:  2009-03-10       Impact factor: 2.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.